Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

BACKGROUND: Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Laurence C., de Kraa, Rebecca, Oommen, Joyce, Chua, Grace-Alyssa, Singh, Sajla, Hughes, Anastasia M., Ferrari, Emanuela, Ford, Jette, Chiu, Sung K., Stam, Ronald W., Kees, Ursula R., Malinge, Sébastien, Kotecha, Rishi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082024/
https://www.ncbi.nlm.nih.gov/pubmed/33937032
http://dx.doi.org/10.3389/fonc.2021.631594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082024/
https://www.ncbi.nlm.nih.gov/pubmed/33937032
http://dx.doi.org/10.3389/fonc.2021.631594

Ejemplares similares